Dishman Carbogen Amcis Reports 22% Q2 Revenue Decline in FY27
Key highlights
- Dishman Carbogen Amcis reported Q2 FY27 revenue of INR 507 crore, down 22% year on year.
- Dishman Carbogen Amcis reported a Q2 FY27 CDMO margin of 12.3%, versus 25.0% a year earlier.
- Dishman Carbogen Amcis reported an H1 FY27 CDMO margin of 8.7%, compared with 21.0% in the prior year.
- Dishman Carbogen Amcis held its investor conference call on 17 August 2026 at 5:00 pm IST.
powered by IRIS

Dishman Carbogen Amcis Limited reported FY27 Q2 revenue of INR 507 crore, a 22% year-on-year decline, while its CDMO margin fell to 12.3% from 25% in the comparable period. The figures place focus on profitability in the company's CDMO operations, even as management discussed technology transfers from Switzerland to India.
Know Dishman Carbogen Amcis inside out
Results, valuation, peers and who's buying, in one view.
What did Dishman Carbogen Amcis report for Q2 FY27?
Dishman Carbogen Amcis reported revenue of INR 507 crore for Q2 FY27, down 22% from the corresponding quarter a year earlier, according to the supplied earnings-call material. The reported revenue movement was accompanied by a steep decline in the CDMO margin, which stood at 12.3% against 25% in the prior-year comparable quarter.
For the first half of FY27, the supplied material puts the CDMO margin at 8.7%, compared with 21% in the previous year. This indicates that margin pressure was not limited to the reported quarter. The material does not state the specific operational, product-mix, pricing, cost, or customer factors behind the revenue decline or the lower margin.
What does the earnings-call disclosure say about the timing?
The disclosure says Dishman Carbogen Amcis held an investor conference call on 17 August 2026 at 5:00 pm IST and made the call recording available on its website. The announcement was filed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and states that the call discussed financial results and performance for the quarter ended 30 June 2026.
There is a timing inconsistency within the supplied material that investors should note. While the announcement describes the 17 August call as relating to the first quarter ended 30 June 2026, the summary accompanying the material characterises the INR 507 crore revenue and margin data as Q2 FY27. The source does not reconcile these labels. Investors assessing period-on-period trends should therefore refer to the complete transcript and the relevant financial results filing for confirmation of the reporting period assigned to each figure.
The supplied material also refers to the transcript as being enclosed and identifies 21 August 2026 as the announcement date. It separately lists a release date of 16 November 2026. These dates establish the availability of the call-related information but do not alter the financial figures cited in the summary.
What operational development did management identify?
Management said Dishman Carbogen Amcis is carrying out multiple technology transfers from Switzerland to India, with the largest transfer expected to reach validation-batch stage in March-April. The company described this project as an important manufacturing and technology-transfer activity within its operations.
The supplied text says the largest transfer is expected to create annual revenue once it is established, but the article does not convert its Swiss-franc revenue indication into INR because no exchange rate or conversion basis was provided in the source. Validation batches are a distinct stage from regular commercial production, so the disclosure should not be read as confirmation that the stated revenue contribution has already been booked.
The planned transfers are relevant because Dishman Carbogen Amcis operates across India and Switzerland. Moving technology into India can affect where products are validated and manufactured, but the material does not provide capital spending, production capacity, customer identity, regulatory approval, or commercial-launch details for the transfers.
Got a follow-up? Ask IRIS
How do the reported figures compare with earlier disclosures?
The reported FY27 margin figures are below levels cited in prior earnings-call material, while older disclosures show that revenue performance has varied across periods and business segments. In a conference call covering the quarter ended 31 December 2025, the company said revenue was about INR 720 crore for that quarter. That figure relates to a different reporting period and should not be treated as a direct like-for-like comparison with the FY27 Q2 figure without the complete financial statements.
Earlier material for the quarter ended 31 December 2024 said the India CRAMS business recorded revenue of INR 77.7 crore, compared with INR 55.5 crore in the comparable prior-year quarter, an increase of 28.5%. These historical figures relate specifically to the India CRAMS business rather than the company-wide FY27 revenue cited in the latest summary.
The available data shows why investors may separate the discussion into two areas: current CDMO margin performance and the potential contribution of technology transfers. The current data point is a reported decline in revenue and margins. The transfer programme is an operational milestone still progressing through validation, with no confirmed revenue recognition timetable disclosed in the supplied material.
Why do the lower margins matter to investors?
The lower CDMO margin matters because it measures the profitability of a core operating area relative to revenue. A decline from 25% to 12.3% in the quarter, and from 21% to 8.7% for the half year, points to materially reduced profitability in the business segment on the reported basis. The source does not provide enough information to quantify the effect on consolidated profit, cash flow, debt, or earnings per share.
For customers and industry participants, the disclosed technology transfers signal continued integration of Swiss capabilities with Indian manufacturing operations. For investors, the key disclosed near-term milestone is the planned validation-batch stage in March-April. No share-price movement, analyst forecast, order-book value, or revised financial guidance is included in the supplied announcement, so those matters cannot be assessed from this disclosure alone.
Conclusion
Dishman Carbogen Amcis has disclosed a weaker revenue and margin position in the supplied FY27 summary, with Q2 revenue of INR 507 crore down 22% year on year and CDMO margin at 12.3%. The data contrasts with earlier periods referenced in past call transcripts and makes the margin trend a central point for evaluating current operating performance.
The next disclosed operational item to watch is progress on the largest Switzerland-to-India technology transfer, which management expects to enter validation batches in March-April. Investors should also seek confirmation from the full transcript and financial-results filing on the reporting-period labels, given the difference between the announcement's Q1 reference and the supplied Q2 FY27 summary.


